{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:58:26Z","timestamp":1774159106823,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Fabry disease (FD) is a lysosomal storage disorder characterized by progressive renal and cardiac involvement and an increased burden of cardiovascular and cerebrovascular events. While cardiac magnetic resonance imaging (CMR) has significantly advanced structural assessment, circulating biomarkers reflecting disease-related cardiac manifestations remain incompletely understood. We therefore investigated adiponectin and leptin, two adipokines involved in inflammatory, metabolic, and fibrotic pathways, in relation to cardiac involvement and analyzed long-term lipid trajectories in FD. Methods: This longitudinal observational study included 49 patients with FD with 149 study visits. Circulating adiponectin, leptin, NT-proBNP, and conventional lipid parameters were assessed longitudinally and stratified by FD-specific therapy status and sex. Multivariable linear regression was performed to evaluate independent associations with log-transformed NT-proBNP values. Results: Adiponectin was positively associated with NT-proBNP, reflecting cardiac involvement, independent of age, sex, BMI, and eGFR (p &lt; 0.001). Higher adiponectin levels were observed in patients with left ventricular hypertrophy or low T1 and those with fibrosis, detected by CMR (p = 0.009 and p &lt; 0.001, respectively). This association was mainly seen in patients receiving FD-specific therapy, raising the question of whether this reflects underlying organ involvement or treatment effects. Leptin demonstrated weaker, inverse associations. Adiponectin, leptin, Triglycerides, total cholesterol, and HDL- and LDL-cholesterol levels remained stable over long-term follow-up, irrespective of FD-specific therapy or sex. Conclusions: In FD, adiponectin appears to be associated with cardiac involvement, and conventional lipid parameters remained unchanged over time. These findings suggest that alterations in adipokines, rather than progressive dyslipidemia, may reflect disease-related cardiac manifestations.<\/jats:p>","DOI":"10.3390\/jcm15062390","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:02:43Z","timestamp":1774026163000},"page":"2390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Adipokine and Lipid Profiles in Fabry Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-085X","authenticated-orcid":false,"given":"Constantin","family":"Gatterer","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8060-0118","authenticated-orcid":false,"given":"Daniela","family":"Allmer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-3827","authenticated-orcid":false,"given":"Dietrich","family":"Beitzke","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-8667","authenticated-orcid":false,"given":"Senta","family":"Graf","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4819-3190","authenticated-orcid":false,"given":"Philipp","family":"Hohensinner","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-1845","authenticated-orcid":false,"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-8354","authenticated-orcid":false,"given":"Eva","family":"Steinacher","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-0044","authenticated-orcid":false,"given":"Alice","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-9921","authenticated-orcid":false,"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-994X","authenticated-orcid":false,"given":"Max","family":"Lenz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: Changing pattern of causes of death in FOS-Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Monda, E., Bakalakos, A., Del Franco, A., Lillo, R., Meucci, M.C., Spinelli, L., Parisi, V., Schiavo, M.A., Rubino, M., and Graziani, F. (2026). Cardiovascular Morbidity and Mortality in Fabry Disease. Circ. Genom. Precis. Med., e005361.","DOI":"10.1161\/CIRCGEN.125.005361"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Azevedo, O., Cordeiro, F., Gago, M.F., Miltenberger-Miltenyi, G., Ferreira, C., Sousa, N., and Cunha, D. (2021). Fabry Disease and the Heart: A Comprehensive Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094434"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101439","DOI":"10.1016\/j.cpcardiol.2022.101439","article-title":"Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring","volume":"48","author":"Umer","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Teresi, L., Trimarchi, G., Licordari, R., Restelli, D., Taverna, G., Liotta, P., Micari, A., Smecca, I., Dendramis, G., and Turturiello, D. (2025). Hypertrophic Cardiomyopathy Phenocopies: Classification, Key Features, and Differential Diagnosis. Biomedicines, 13.","DOI":"10.20944\/preprints202510.2086.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e041627","DOI":"10.1161\/JAHA.124.041627","article-title":"Evolution of Cardiac Damage Staged With Echocardiography in Fabry Disease","volume":"14","author":"Lillo","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry Disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Umer, M., and Kalra, D.K. (2022). Cardiac MRI in Fabry disease. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1075639"},{"key":"ref_12","first-page":"e12083","article-title":"Stroke and Fabry Disease: A Review of Literature","volume":"12","author":"Mishra","year":"2020","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12350-023-03205-7","article-title":"Detection of sympathetic denervation defects in Fabry disease by hybrid [(11)C]meta-hydroxyephedrine positron emission tomography and cardiac magnetic resonance","volume":"30","author":"Gatterer","year":"2023","journal-title":"J. Nucl. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12350-019-01734-8","article-title":"Focal reduction in left ventricular (123)I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease","volume":"28","author":"Spinelli","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kurdi, H., Lavalle, L., Moon, J.C.C., and Hughes, D. (2024). Inflammation in Fabry disease: Stages, molecular pathways, and therapeutic implications. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1420067"},{"key":"ref_16","first-page":"196","article-title":"The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies","volume":"23","author":"Pieroni","year":"2022","journal-title":"RCM"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"534320","DOI":"10.1155\/2015\/534320","article-title":"Differential Role of Leptin and Adiponectin in Cardiovascular System","volume":"2015","author":"Ghantous","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Komi\u0107, L., Komi\u0107, J., Pavlovi\u0107, N., Kumri\u0107, M., Buki\u0107, J., Jeron\u010di\u0107 Tomi\u0107, I., and Bo\u017ei\u0107, J. (2026). The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27020612"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12965\/jer.140100","article-title":"Role of adiponectin in metabolic and cardiovascular disease","volume":"10","author":"Lee","year":"2014","journal-title":"J. Exerc. Rehabil."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jjcc.2013.11.006","article-title":"Adipokines: A link between obesity and cardiovascular disease","volume":"63","author":"Nakamura","year":"2014","journal-title":"J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Karmazyn, M., and Gan, X.T. (2025). Beyond Leptin and Adiponectin: The Diverse Roles of Adipokines in the Myocardial Hypertrophic Process and Heart Failure and Their Potential Contribution in Obesity. Int. J. Mol. Sci., 27.","DOI":"10.20944\/preprints202511.2058.v1"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., and Nikolaou, M. (2024). Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review. Diagnostics, 14.","DOI":"10.3390\/diagnostics14232677"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.mayocp.2016.03.020","article-title":"Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox","volume":"91","author":"Wolk","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102379","DOI":"10.1016\/j.bcmd.2019.102379","article-title":"Plasma adiponectin is a potential biomarker for organ involvement in male Fabry disease patients","volume":"80","author":"Hovakimyan","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107585","DOI":"10.1016\/j.ymgme.2023.107585","article-title":"An expert consensus on the recommendations for the use of biomarkers in Fabry disease","volume":"139","author":"Burlina","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gatterer, C., Beitzke, D., Sunder-Plassmann, G., Friedl, M., Hohensinner, P., Mann, C., Ponleitner, M., Graf, S., and Lenz, M. (2024). NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195953"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update","volume":"22","author":"Kramer","year":"2020","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcmg.2014.01.016","article-title":"Association of CMR-measured LA function with heart failure development: Results from the MESA study","volume":"7","author":"Habibi","year":"2014","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12968-014-0069-x","article-title":"Reference values for healthy human myocardium using a T1 mapping methodology: Results from the International T1 Multicenter cardiovascular magnetic resonance study","volume":"16","author":"Dabir","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"22","author":"Hetzel","year":"2020","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/CIRCRESAHA.120.314458","article-title":"Adiponectin, Leptin and Cardiovascular Disorders","volume":"128","author":"Zhao","year":"2021","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Carella, M.C., Forleo, C., Caretto, P., Naccarati, M.L., Dentamaro, I., Dicorato, M.M., Basile, P., Carulli, E., Latorre, M.D., and Baggiano, A. (2024). Overcoming Resistance in Anderson-Fabry Disease: Current Therapeutic Challenges and Future Perspectives. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237195"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109709","DOI":"10.1016\/j.ymgme.2025.109709","article-title":"Diagnosis, treatment, and follow-up of Fabry disease in pediatrics","volume":"147","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Forleo, C., Carella, M.C., Basile, P., Mandunzio, D., Greco, G., Napoli, G., Carulli, E., Dicorato, M.M., Dentamaro, I., and Santobuono, V.E. (2024). The Role of Magnetic Resonance Imaging in Cardiomyopathies in the Light of New Guidelines: A Focus on Tissue Mapping. J. Clin. Med., 13.","DOI":"10.20944\/preprints202403.1108.v1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.31083\/j.rcm2305177","article-title":"Cardiac Magnetic Resonance Features of Fabry Disease: From Early Diagnosis to Prognostic Stratification","volume":"23","author":"Camporeale","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Laffer, B., Lenders, M., Ehlers-Jeske, E., Heidenreich, K., Brand, E., and K\u00f6hl, J. (2024). Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1307558"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Zhao, Y., Li, F., Ling, C., Wu, Y., Ma, W., Wang, Z., Yuan, Y., Hao, H., and Zhang, W. (2024). Inflammatory cytokine expression in Fabry disease: Impact of disease phenotype and alterations under enzyme replacement therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1367252"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1007\/s00210-024-03499-5","article-title":"Long-term enzyme replacement therapy in Fabry patients protects against oxidative and inflammatory process","volume":"398","author":"Moura","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13023-025-03705-4","article-title":"Current status of the immunogenicity of enzyme replacement therapy in fabry disease","volume":"20","author":"Ortolano","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Licordari, R., Trimarchi, G., Teresi, L., Restelli, D., Lofrumento, F., Perna, A., Campisi, M., de Gregorio, C., Grimaldi, P., and Calabr\u00f2, D. (2023). Cardiac Magnetic Resonance in HCM Phenocopies: From Diagnosis to Risk Stratification and Therapeutic Management. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103481"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed Stages of Myocardial Phenotype Development in Fabry Disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1093\/ehjci\/jeaa271","article-title":"Histogram features of Fabry disease with pseudonormalization in native T1 mapping","volume":"22","author":"Oda","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Trimarchi, G., Carerj, M.L., Zito, C., Bella, G.D., Taverna, G., Cusm\u00e0 Piccione, M., Crea, P., Lo Giudice, S., Buonpane, A., and Bonanni, M. (2025). Epicardial Adipose Tissue: A Multimodal Imaging Diagnostic Perspective. Medicina, 61.","DOI":"10.3390\/medicina61060961"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ytac419","DOI":"10.1093\/ehjcr\/ytac419","article-title":"Cardiac fibroblast activation in Fabry disease on (18)F-fibroblast activation protein inhibitor positron emission tomography\/computed tomography imaging","volume":"6","author":"Wang","year":"2022","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/cfr.2023.06","article-title":"Cardiovascular Involvement in Fabry\u2019s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management","volume":"9","author":"Monda","year":"2023","journal-title":"Card. Fail. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10554-023-02818-w","article-title":"The value of myocardial work in patients with left ventricular hypertrophy","volume":"39","author":"Fan","year":"2023","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s001250050804","article-title":"Plasma leptin concentrations: Gender differences and associations with metabolic risk factors for cardiovascular disease","volume":"40","author":"Couillard","year":"1997","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOL.0000000000000536","article-title":"Sex differences in metabolism and cardiometabolic disorders","volume":"29","author":"Mehrabian","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_55","first-page":"3","article-title":"Lipid profile in adult patients with Fabry disease-Ten-year follow up","volume":"13","author":"Stepien","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12020-021-02918-4","article-title":"Endocrine disorders in patients with Fabry disease: Insights from a reference centre prospective study","volume":"75","author":"Bothou","year":"2022","journal-title":"Endocrine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1023\/B:BOLI.0000045841.27968.06","article-title":"Raised HDL cholesterol in Fabry disease: Response to enzyme replacement therapy","volume":"27","author":"Cartwright","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:11:04Z","timestamp":1774156264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15062390"],"URL":"https:\/\/doi.org\/10.3390\/jcm15062390","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}